The replacement of heart valves only became feasible after the development of the heart-lung machine in 1953. Two groups of prosthetic heart valves were subsequently developed: biological valves that do not require anticoagulation and mechanical valves that require life-long anticoagulation with Coumadin. The incidence of heart surgery and the demographics of patients who require heart valve surgery vary worldwide; these factors influence the choice of prosthetic valve for the individual patient and are briefly reviewed. Improved biological tissue-fixation methods are also increasing the durability of biological prosthetic valves and will further favor the implantation of biological valves in the future.